Be Kind to Your Genes: An Insurance Perspective on the Fast-Growing Field of Epigenetics
Eat your vegetables. Stay active. Avoid smoking. Keep out of the sun. Patients have been hearing this good advice from their doctors for a long time. Now, researchers are uncovering new evidence that our lifestyle choices can measurably influence mortality risk at a genetic level. Learn more about the emerging science of epigenetics in a two-part interview and the webinar “Epigenetics and Liquid Biopsies: Fact, Fiction or Both.”
How Wearable Technology Presents Opportunity For Insurers
Wearable devices (those worn by consumers as accessories or implants), have been of interest to more than a handful of industries in recent years. The opportunities and possible uses so far seem positive and limitless.
Frictionless Business and the Future of Life Insurance
The age of traditional business partnerships is long past. Today, strategic partnerships offer life insurers the ability to expand their businesses into new ecosystems. Whether investing in insurtechs or collaborating with partners in complementary industries, life insurers can build partnerships based not only on strategy, product and services but also on the merging of technology and the sharing of platforms.
How Liquid Biopsies Could Transform Insurance Medicine
Cancerous tumors shed whole cells or tiny bits of DNA and other genetic material into the bloodstream and other bodily fluids. This allows clinicians to potentially analyze blood samples to detect a tumor's unique mutations and offer a personalized treatment regimen, all without an invasive tissue biopsy.
From its earliest days, life insurance has been fueled by data. Today, the industry is more data-driven than ever. Life insurers rely on data to make better operational, risk and pricing decisions. They use data to develop new products and business models. Increasingly, they leverage data to incentivize customers to reduce their exposure to risks and help them avoid incurring losses.
A difficult and often fatal disease in older adults, idiopathic pulmonary fibrosis (IPF) is one of a spectrum of diseases called interstitial lung disease. The title accurately describes the process: Idiopathic (cause is unknown), pulmonary (affecting the lungs) and fibrosis (the normally expansive tissue in the lungs becomes hardened and fibrous). The disease can be localized or generalized, with generalized findings having a particularly poor prognosis. Usually not found until its later stages, CT scanning (particularly for lung cancer screening) has shown IPF to be more prevalent than previously thought.
Have you noticed that the word invasive is being bandied about more and more often in underwriting-related articles and commentaries published online and in various industry publications? This is mainly being done by those advocating radical changes in underwriting practices.
The purpose of this paper is to discuss the insurability implications of low normal/ below normal ALT in the elderly… in the hope that insurers will consider adding appropriate guidelines for this finding at older ages.